Update shared on08 Oct 2025
Fair value Decreased 6.66%Narrative Update on Xvivo Perfusion
Analysts have lowered their fair value estimate for Xvivo Perfusion to SEK 322.6 from SEK 345.6. The updated price target reflects revised assumptions on profit margins and revenue growth, as well as increased confidence signaled by a recent upgrade to Buy.
Analyst Commentary
Analysts have provided updated perspectives following the recent price target adjustment and rating upgrade for Xvivo Perfusion. Evaluations focus on the company's operational performance, growth prospects, and risks to execution.
Bullish Takeaways
- Bullish analysts cite strong revenue momentum, supported by growing demand for organ transplantation solutions and innovative perfusion technologies.
- Recent improvements in profit margins indicate operational leverage, lending support to a higher valuation multiple.
- The strategic upgrade to Buy reflects increased confidence in management's execution and the company's ability to capture key market opportunities.
- The assigned price target points to potential upside from current price levels, based on rising adoption of Xvivo's product portfolio.
Bearish Takeaways
- Analysts express some caution regarding margin sustainability, noting that competitive pressures and investment needs could weigh on profitability.
- Revenue forecasts remain sensitive to execution risks, particularly in newer product and geographic segments.
- Valuation remains elevated relative to peers, which could limit further upside if operational improvement does not accelerate as anticipated.
What's in the News
- Xvivo Perfusion has enrolled the first patient in the Continued Access Protocol (CAP) study for its XVIVO Heart Assist Transport technology in the United States. (Key Developments)
- The CAP study follows the successful PresERVE Trial and allows up to 60 patients to be enrolled at 26 transplant centers across the US. (Key Developments)
- The study has received continued cost recovery approval from the Centers for Medicare & Medicaid Services (CMS), providing support for participating centers and patients. (Key Developments)
- The protocol, approved by the US FDA, enables ongoing clinical use of the Heart Assist Transport device while one-year follow-up data are collected for Pre-Market Approval (PMA) submission. (Key Developments)
Valuation Changes
- The Fair Value Estimate has declined from SEK 345.6 to SEK 322.6, reflecting a modest downward revision.
- The Discount Rate has fallen slightly to 5.50% from 5.58%.
- The Revenue Growth assumption has decreased marginally, now at 30.09% compared to the previous estimate of 30.74%.
- The Net Profit Margin projection has dropped to 15.24% from 16.56%.
- The Future P/E Ratio has increased, now at 42.54x compared to 41.41x previously.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.